Mannion Melissa L, Xie Fenglong, Baddley John, Chen Lang, Curtis Jeffrey R, Saag Kenneth, Zhang Jie, Beukelman Timothy
Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Ave S, CPPN M10, Birmingham, AL, 35209, USA.
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 510 20th St South, FOT 802, Birmingham, AL, 35294, USA.
Pediatr Rheumatol Online J. 2016 Sep 5;14(1):49. doi: 10.1186/s12969-016-0107-3.
To investigate the utilization of health care services before and after transfer from pediatric to adult rheumatology care in clinical practice.
Using US commercial claims data from January 2005 through August 2012, we identified individuals with a JIA diagnosis code from a pediatric rheumatologist followed by any diagnosis code from an adult rheumatologist. Individuals had 6 months observable time before the last pediatric visit and 6 months after the first adult visit. Medication, emergency room, physical therapy use, and diagnosis codes were compared between the pediatric and adult interval using McNemar's test. The proportion of days covered (PDC) of TNFi for the time between last pediatric and first adult visit was calculated.
We identified 58 individuals with JIA who transferred from pediatric to adult rheumatology care after the age of 14. The median age at the last pediatric rheumatology visit was 18.1 years old and the median transfer interval was 195 days. 29 % of patients received NSAIDs in the adult interval compared to 43 % in the pediatric interval (p = 0.06). In the pediatric interval, 71 % received a JRA and 0 % received an RA physician diagnosis code compared to 28 and 45 %, respectively, in the adult interval. The median PDC for patients receiving a TNFi was 0.75 during the transfer interval.
Individuals with JIA who transferred to adult care were more likely receive a diagnosis of RA instead of JRA and were less likely to receive NSAIDs, but had no significant immediate changes to other medication use.
在临床实践中调查从儿科转至成人风湿病护理前后的医疗服务利用情况。
利用2005年1月至2012年8月的美国商业索赔数据,我们识别出患有幼年特发性关节炎(JIA)诊断代码且随后有成人风湿病医生的任何诊断代码的个体。个体在最后一次儿科就诊前有6个月的可观察时间,在第一次成人就诊后有6个月的可观察时间。使用McNemar检验比较儿科和成人期间的药物使用、急诊室就诊、物理治疗使用及诊断代码。计算最后一次儿科就诊和第一次成人就诊之间英夫利昔单抗(TNFi)的覆盖天数比例(PDC)。
我们识别出58名14岁后从儿科转至成人风湿病护理的JIA患者。最后一次儿科风湿病就诊的中位年龄为18.1岁,中位转诊间隔为195天。29%的患者在成人期间使用非甾体抗炎药(NSAIDs),而在儿科期间为43%(p = 0.06)。在儿科期间,71%的患者有幼年类风湿关节炎(JRA)诊断代码,0%有类风湿关节炎(RA)医生诊断代码,而在成人期间分别为28%和45%。在转诊期间,接受TNFi治疗的患者的中位PDC为0.75。
转至成人护理的JIA患者更有可能被诊断为RA而非JRA,且使用NSAIDs的可能性较小,但其他药物使用没有明显的即刻变化。